Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review

Liver Cancer

In: Cancer: Disease Control Priorities, Third Edition (Volume 3). Washington (DC): The International Bank for Reconstruction and Development / The World Bank; 2015 Nov 1. Chapter 8.
Free Books & Documents
Review

Liver Cancer

Hellen Gelband et al.
Free Books & Documents

Excerpt

Deaths from liver cancer are common, especially in East Asia and Pacific, South Asia, and parts of Sub-Saharan Africa, largely as a result of infection decades ago. As the toll from other cancers is likely to climb in the coming decades, however, liver cancer incidence and mortality rates should fall, as generations vaccinated against the hepatitis B virus (HBV)—the cause of most liver cancers globally—reach middle and old age. Much still needs to be done and it is feasible and affordable to hasten the decline. Much can also be done to address other causes of liver cancer—including some on the rise, in particular, obesity-related non-alcoholic fatty liver disease (NAFD)—in the coming years and decades. The latter half of the twentieth century witnessed the identification of the main causes of liver cancer and deployment of the first cancer prevention vaccine for humans. All of the risk factors that lead to cirrhosis cause at least as many noncancer deaths as cancer deaths. Controlling these risk factors would not only reduce the incidence of liver cancer; it would also reduce the incidence of cirrhosis and its other complications, notably, end-stage liver disease and portal hypertension.

PubMed Disclaimer

References

    1. Aggarwal R, Ghoshal U C, Naik S R. 2002. “Treatment of Chronic Hepatitis B with Interferon-Alpha: Cost-Effectiveness in Developing Countries.” The National Medical Journal of India 15 (6): 320–27. http://www.ncbi.nlm.nih.gov/pubmed/12540064. - PubMed
    1. Aggarwal R, Ghoshal U C, Naik S R. 2003. “Assessment of Cost-Effectiveness of Universal Hepatitis B Immunization in a Low-Income Country with Intermediate Endemicity Using a Markov Model.” Journal of Hepatology 38 (2): 215–22. http://www.ncbi.nlm.nih.gov/pubmed/12547411. - PubMed
    1. Ahmad K. 2004. “Pakistan: A Cirrhotic State?” The Lancet 364 (9448): 1843–44. doi:10.1016/S0140-6736(04)17458-8. - PubMed
    1. Alcorn T. 2011. “Mongolia’s Struggle with Liver Cancer.” The Lancet 377 (9772): 1139–40. http://www.ncbi.nlm.nih.gov/pubmed/21465699. - PubMed
    1. Allen N E, Beral V, Casabonne D, Kan S W, Reeves G K. others. 2009. “Moderate Alcohol Intake and Cancer Incidence in Women.” Journal of the National Cancer Institute 101 (5): 296–305. http://www.ncbi.nlm.nih.gov/pubmed/19244173. - PubMed

LinkOut - more resources